Skip to content
value.today
DBV Technologies S.A. logo

DBV Technologies S.A.

DBV.PA
$194 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$6 M
For year ending December-2025
value.today research
Net income
$-188 M
-3337.1% margin
value.today research
Employees
—

DBV Technologies S.A. in brief

DBV Technologies S.A. is a listed company in the Biotechnology industry, based in France. It was founded in 2002. Its last known market value was $194 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $6 M and a net loss of $188 M. Its shares trade under the symbol DBV.PA (EURONEXT).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About DBV Technologies S.A.

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies S.A. timeline

3 events, 2002–2017
  1. 2002
  2. 🏁
    · approximate
    Founded
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq as DBVT
  5. 2017
  6. •
    Legal Entity Identifier issued
    LEI 969500PVBQFWQKVDMD80 registered.

Events of DBV Technologies S.A. from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$290 M$580 M$870 M$1.2 B20202021202220232024

World rank over time

▼ down 10,743 places since 2020
2020-01-01: #7338#7,33820202021-01-01: #13870#13,87020212022-01-07: #19179#19,17920222022-12-25: #16182#16,18220222023-07-30: #14520#14,52020232024-01-05: #18081#18,0812024

Rank in France: #135 (Jan 2020) · #249 (Jan 2021) · #284 (Jan 2022) · #231 (Dec 2022) · #208 (Jul 2023) · #250 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-3337.1%
Operating margin
-2607.4%
Return on equity
-111.5%
Liabilities / assets
27.8%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-114M—FY24Fiscal year ending Dec 2025: revenue —, net income $-147M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-147M$-147M—
Dec 2024——$-116M$-114M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-120M——$-1.05—
Dec 2024$-103M——$-1.18—

Annual results

Revenue
$6 M
Operating income
$-147 M
Net income
$-188 M

For year ending December-2025

Balance sheet

Total assets
$234 M
Total liabilities
$65 M
Total equity
$169 M

As of December-2025

Mutual funds holding DBV Technologies S.A.#

10 funds hold shares worth $5 M. Since their previous reports 10 added shares and 0 sold, buying $5 M net.
Mutual funds holding DBV Technologies S.A.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors653,086$2 M—<0.01%newJul 31, 2026
🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors634,957$2 M—0.01%newJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC117,668$0 M—<0.01%newJun 30, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.104,702$0 M—0.04%+18%Jun 30, 2026
🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC108,080$0 M—<0.01%newJul 31, 2026
🇺🇸 iShares Core MSCI Europe ETFBlackRock Fund Advisors96,952$0 M—<0.01%newJul 31, 2026
🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC51,082$0 M—0.01%newJul 31, 2026
🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors40,838$0 M—<0.01%newJul 31, 2026
🇺🇸 iShares MSCI Europe Small-Cap ETFBlackRock Fund Advisors19,925$0 M—0.03%newJul 31, 2026
🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc.8,318$0 M—<0.01%+152%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

DBV Technologies S.A. scorecard#

Passes 0 of the 3 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.05 vs -1.18Diluted EPS -1.05 in fiscal 2025 against -1.18 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$147 MNet income -$147 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-150.0%-150.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

DBV Technologies S.A.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

DBV Technologies S.A.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue——0000
Research and development11789607570101
Total costs and expenses15312192101104169
Operating income−147−116−76−96−98−158
Interest and finance income2.83.95.00.70.50.2
Interest expense and finance costs2.61.51.40.40.72.0
Income tax0.50.10.00.1−0.4−0.0
Net income including minority interests−147−114−73−96−98−160
Earnings per share, basic-1.05-1.18-0.76-1.24——
Earnings per share, diluted-1.05-1.18-0.76-1.24——
Balance sheet
Cash and cash equivalents1943214120977196
Receivables——0002.2
Other current assets——1814378.8
Current assets21344159223115207
Property, plant and equipment101113151825
Right-of-use (leased) assets4.35.45.32.56.89.9
Other intangible assets0.00.00.10.00.00.0
Non-current assets202124233265
Total assets23366183246146272
Accounts payable————1120
Debt due within a year——000.50.7
Current liabilities583137303153
Long-term debt——0000.5
Lease liabilities (non-current)5.46.34.51.27.110
Non-current liabilities6.67.05.3221614
Shareholders' equity1692714019499205
Total equity16927————
Total liabilities and equity23366183246146272
Shares outstanding23610396945555
Cash-flow statement
Share-based compensation5.44.66.05.03.1−1.1
Cash from operating activities−120−103−78−51−104−161
Capital expenditure——−0.7−0.8−0.9−2.8
Intangible assets bought——00−0.0−0.0
Cash from investing activities−1.4−0.8−0.8−0.1−0.4−2.9
Debt issued——0000
Debt repaid——0−0.5−0.7−0.3
Shares issued——6.91940.8150
Cash from financing activities275−0.74.8190−3.9145
Exchange-rate effect on cash8.1−4.35.9−6.5−1122
Change in cash————−108−19
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How DBV Technologies S.A. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
DBV Technologies S.A.🇫🇷$194 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 9, 2026

Figures from value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at DBV Technologies S.A.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show DBV Technologies S.A.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about DBV Technologies S.A.? Suggest a correction